Skip to main content
Figure 1 | Orphanet Journal of Rare Diseases

Figure 1

From: Sustainable rare diseases business and drug access: no time for misconceptions

Figure 1

A comparison of the top 5 European countries’ mean price treatments for OMPs and mean price treatments for a select sample of non-rare disease hospital-specialty drugs (%indicate the share percentage of each category in all approved OMPs in Europe as of December 2012 ). (*)Mabcampath, Mabthera ,Tasigna ,Velcade,Sutent, Herceptin, Avastin, Iressa / (**) Humira, Enbrel, Remicade, Mabthera.

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172